Tempus in the Times20 Apr 2007 08:46
It has been a rough ride, at times, for shareholders in this biotechnology group. The share price quadrupled between autumn 2003 and spring 2004 as the market enjoyed promising news flow. In April 2004, however, the shares collapsed when it encountered setbacks in its research programme and the dissolution of a development deal with Roche.
Confidence began to be rebuilt with a successful cash call in late 2005 and news yesterday of a new link, this time with Novartis, has helped the stock recover lost ground.
The Novartis deal, including £50 million in upfront and near term payments, secures Antisoma's finances for the foreseeable future and opens potential market opportunities in the US. Hopes are that Antisoma will be able to bring forward several compounds, designed to treat different cancers. As with many biotechs, the risks are high. But so are the rewards. Buy.